ALK and neuroblastoma: Many of these clinical trials have shown that ALK inhibition also sensitized tumours to standard-of-care chemotherapy, supporting the combination of ALK inhibitors with current standard-of-care treatments for the small number of patients with ALK mutant neuroblastoma.